How are INCY straddle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the INCY straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 40.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$919.70 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a INCY straddle?

The breakeven for the INCY straddle priced on this page is roughly $85.35 and $104.65 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current INCY market-implied 1-standard-deviation expected move is approximately 11.50%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current INCY implied volatility affect this straddle?

INCY ATM IV is at 40.10% with IV rank near 45.57%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

INCY Straddle Strategy

INCY (Incyte Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma.

INCY (Incyte Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $19.74B, a trailing P/E of 13.76, a beta of 0.80 versus the broader market, a 52-week range of 61.11-112.29, average daily share volume of 1.5M, a public-listing history dating back to 1993, approximately 3K full-time employees. These structural characteristics shape how INCY stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.80 places INCY roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a straddle on INCY?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current INCY snapshot

As of May 15, 2026, spot at $95.93, ATM IV 40.10%, IV rank 45.57%, expected move 11.50%. The straddle on INCY below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this straddle structure on INCY specifically: INCY IV at 40.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 11.50% (roughly $11.03 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated INCY expiries trade a higher absolute premium for lower per-day decay. Position sizing on INCY should anchor to the underlying notional of $95.93 per share and to the trader's directional view on INCY stock.

INCY straddle setup

The INCY straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With INCY near $95.93, the first option leg uses a $95.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed INCY chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 INCY shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$95.00	$5.45
Buy 1	Put	$95.00	$4.20

INCY straddle risk and reward

Net Premium / Debit: -$965.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$919.70
Breakeven(s): $85.35, $104.65
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

INCY straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on INCY. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$8,534.00
$21.22	-77.9%	+$6,413.05
$42.43	-55.8%	+$4,292.09
$63.64	-33.7%	+$2,171.14
$84.85	-11.6%	+$50.18
$106.06	+10.6%	+$140.77
$127.27	+32.7%	+$2,261.73
$148.48	+54.8%	+$4,382.68
$169.69	+76.9%	+$6,503.64
$190.90	+99.0%	+$8,624.59

When traders use straddle on INCY

Straddles on INCY are pure-volatility plays that profit from large moves in either direction; traders typically buy INCY straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

INCY thesis for this straddle

The market-implied 1-standard-deviation range for INCY extends from approximately $84.90 on the downside to $106.96 on the upside. A INCY long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current INCY IV rank near 45.57% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on INCY should anchor more to the directional view and the expected-move geometry. As a Healthcare name, INCY options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to INCY-specific events.

INCY straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. INCY positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move INCY alongside the broader basket even when INCY-specific fundamentals are unchanged. Always rebuild the position from current INCY chain quotes before placing a trade.

Frequently asked questions

What is a straddle on INCY?: A straddle on INCY is the straddle strategy applied to INCY (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With INCY stock trading near $95.93, the strikes shown on this page are snapped to the nearest listed INCY chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are INCY straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the INCY straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 40.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$919.70 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a INCY straddle?: The breakeven for the INCY straddle priced on this page is roughly $85.35 and $104.65 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current INCY market-implied 1-standard-deviation expected move is approximately 11.50%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on INCY?: Straddles on INCY are pure-volatility plays that profit from large moves in either direction; traders typically buy INCY straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current INCY implied volatility affect this straddle?: INCY ATM IV is at 40.10% with IV rank near 45.57%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.